RE-APPOINTMENT OF MR. SANJAY SETHI (DIN: 00090277) AS MANAGING DIRECTOR OF THE COMPANY FOR A PERIOD OF FIVE YEARS

Management Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹22.24

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-1.4% vs market

Pharmaceuticals peers, median of 152sector+1.0%-1.0% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.4-1.4+1.0-1.0

Next day

+5.4+2.7+2.7+1.4+4.1

+7.9+2.4+5.4+1.3+6.6

+3.4+2.2+1.2+0.7+2.7

-1.1+1.9-3.0+0.3-1.3

+5.7+2.1+3.6+0.6+5.1

+0.7+2.3-1.5+1.0-0.3

15d

+7.2+3.4+3.9+0.6+6.6

+3.6+5.0-1.4+1.9+1.7

+2.2+0.8+1.4-2.7+5.0

+7.7-1.3+9.0-4.2+11.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs Ltd has re-appointed Mr. Sanjay Sethi (DIN: 00090277) as Managing Director for a further term of 5 years, effective 11 December 2025. The re-appointment was approved by shareholders at the Annual General Meeting held on 30 September 2025. Mr. Sethi is around 62 years old, holds a B. Pharma degree, and has 43 years of experience. The filing confirms he is not debarred from holding office by any SEBI order. He is disclosed as related to a director on the board.

Likely market impact

Continuity in leadership at the top management level, which is generally a stability signal for shareholders. No change in strategic direction or governance structure is indicated by this routine re-appointment.